(CercleFinance.com) – The Biosenic study dedicated to the healing of difficult fractures gave negative results, thus leading to a suspension of the trial, announced Monday the biotechnology company.
The former Bone-Therapeutics – specializing in cell repair – justifies its decision by the fact that its interventional study around ALLOB, its flagship product, did not reach the main endpoint of the phase IIb trial.
The objective of this study was to evaluate the effectiveness of administering ALLOB, a derivative of mesenchymal stem cells, immediately after a complicated bone fracture, in order to accelerate healing.
Unlike the previous successful phase, the early application of ALLOB did not accelerate the healing process, Biosenic says.
The title thus lost more than 26% on Euronext Paris late Monday morning.
Following this failure, BioSenic plans to focus its resources on its most promising and advanced asset, Medsenic’s OATO platform for autoimmune diseases.
This will allow the company to focus on the advanced phase III trial of oral arsenic trioxide, targeting chronic graft versus host disease, which is the subject of an ongoing procedure with the US FDA. .
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Are you following this action?
Receive all the information about BONE THERAPEUTICS in real time: